Regenerative medicine and cell therapy by Lineage Cell Therapeutics
Lineage Cell Therapeutics joins panel on novel treatments at Clinical Trials at the Summit
Lineage Cell Therapeutics participated in the “From Innovation to Approval: Bringing Novel Treatments to Market” panel at Clinical Trials at the Summit 2026. The event, hosted by CTS Tahoe ...
Lineage Cell Therapeutics spotlights CEO participation in fireside chat with HCWCO at BioConnect
Lineage Cell Therapeutics participated in the 4th Annual BioConnect Investor Conference, hosted by HCWCO at the Nasdaq Exchange. Dr. Joe Pantginis of HCWCO moderated a fireside chat with Brian ...
Lineage Cell Therapeutics featured in European Pharmaceutical Review report on scalable cell therapies
Lineage Cell Therapeutics has been featured in the 2026 Cell and Gene Therapy report by European Pharmaceutical Review, with CEO Brian Culley providing insight into the development of scalable, ...
Lineage Cell Therapeutics holds investor call after releasing first quarter 2026 results
Lineage Cell Therapeutics has announced its financial results for the first quarter of 2026, with an investor conference call set for 4:30 pm ET today to deliver a business update. The company ...
Lineage Cell Therapeutics presents 3-year Phase 1-2a OpRegen trial results in geographic atrophy at summit
Lineage Cell Therapeutics revealed new results from its 3-year Phase 1-2a clinical study of OpRegen (RG6501) in patients with geographic atrophy (GA) secondary to age-related macular degeneration ...
Lineage Cell Therapeutics launches COR1 for corneal diseases amid rising FECD prevalence
Lineage Cell Therapeutics has announced its entry into the market for corneal endothelial disease with the introduction of COR1, targeting the growing global population affected by Fuchs ...
Lineage Cell Therapeutics pushes scalable platforms to address drug discovery complexity
Lineage Cell Therapeutics draws attention to the increasing challenges in drug discovery. Chief Executive Officer Brian Culley, speaking with BioSpace, points to the urgent need for scalable ...
Lineage Cell Therapeutics unveils preclinical therapy for Fuchs dystrophy and Bullous Keratopathy
Lineage Cell Therapeutics has announced the launch of COR1, a preclinical corneal endothelial cell therapy program developed for patients with corneal endothelial disease. The COR1 initiative is ...
Lineage Cell Therapeutics posts fourth quarter and full year 2025 financial results ahead of update call
Lineage Cell Therapeutics released its financial results for both the fourth quarter and full year 2025, providing insights into the company’s recent performance. The biotech firm will hold a ...
Lineage Cell Therapeutics explores future of dry AMD treatment
Lineage Cell Therapeutics took part in the insightful discussions at the Ocular Innovations Summit in San Diego. CEO Brian Culley participated in a panel focusing on the future outlook of dry ...
Lineage Cell Therapeutics advances regenerative medicine with scalable therapies
Lineage Cell Therapeutics is at the forefront of regenerative medicine, focusing on scalable, allogeneic cell therapies to restore lost function. Their CEO, Culley, was recently featured by ...
Lineage Cell Therapeutics to release Q3 2025 results, hosts business update call
Lineage Cell Therapeutics announced that it will release its financial and operating results for the third quarter of 2025 on Thursday, November 6, 2025. The company is set to host a conference ...
Lineage Cell Therapeutics CEO to attend ophthalmology annual meeting
Lineage Cell Therapeutics' CEO, Brian Culley, will be attending the American Academy of Ophthalmology (AAO) Annual Meeting in Orlando, Florida, from October 18-21. The AAO meeting is a ...
